Russia to Launch Free Personalized mRNA Cancer Vaccine by 2025
Russia has developed a free personalized mRNA cancer vaccine using AI to target tumors. Human trials start in late 2025, with rollout expected early that year.
Russia has announced a groundbreaking development: a personalized mRNA-based cancer vaccine, set to be distributed free of charge to patients beginning early 2025.
The vaccine is being developed by the Gamaleya National Research Center for Epidemiology and Microbiology the same institute behind the Sputnik V COVID-19 vaccine in collaboration with leading Russian medical research centers.
What sets this cancer vaccine apart is its personalization. Using AI to analyze tumor genetics, the vaccine targets specific neoantigens unique markers on a patient’s tumor to trigger an immune response that attacks cancer cells. In pre-clinical trials, researchers reported a 75–80% reduction in tumor size and prevention of metastasis in test subjects.
A melanoma-specific version of the vaccine is expected to enter human clinical trials by late 2025, conducted at the Hertsen Research Institute and N.N. Blokhin National Medical Research Center in Moscow.
If successful, the project could position Russia at the forefront of personalized oncology treatment and drastically reduce cancer mortality for patients with access to this AI-driven vaccine therapy. ? @gettyimage
